Telix Pharmaceuticals (TLX) vs Xenon Pharmaceuticals (XENE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Telix Pharmaceuticals (TLX) has outperformed Xenon Pharmaceuticals (XENE) over the past year, gaining 11.8% versus a loss of 7.0%. Telix Pharmaceuticals is the larger company by market cap ($3.75 billion vs $3.51 billion), about 1.1 times the size. Telix Pharmaceuticals converts more of its revenue into profit, with a net margin of -0.9% versus -4612.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TLX | XENE |
|---|---|---|
| Share price | $11.04 | $36.23 |
| Market cap | $3.75B | $3.51B |
| 1-day change | -0.72% | -0.49% |
| YTD return | +48.46% | -18.76% |
| 1-year return | +11.76% | -7.02% |
| 5-year return | — | +8.17% |
| P/E ratio (TTM) | 110.40 | — |
| EPS (TTM) | $0.10 | $-4.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $803.79M | $7.50M |
| Revenue growth (YoY) | +55.61% | — |
| Net income (latest FY) | $-7.13M | $-345.91M |
| Gross margin | 53.05% | — |
| Operating margin | 3.70% | -4974.27% |
| Net margin | -0.89% | -4612.13% |
| 52-week high | $13.11 | $72.66 |
| 52-week low | $6.28 | $35.06 |
| Distance from 52-week high | -15.79% | -50.14% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +84.96% | +102.51% |
| Average volume | 258.23K | 1.43M |
| Shares outstanding | 339.78M | 96.84M |
| Employees | 1,120 | 358 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TLX has outperformed XENE by 18.8 percentage points over the past year.
- Telix Pharmaceuticals is more profitable, keeping -0.9 cents of every revenue dollar as net income versus -4612.1 cents for Xenon Pharmaceuticals.
About Telix Pharmaceuticals
TLX stock →Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,120 employees
About Xenon Pharmaceuticals
XENE stock →Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression.
Health Care · Biotechnology: Pharmaceutical Preparations · 358 employees
TLX vs XENE FAQ
Which is bigger, Telix Pharmaceuticals or Xenon Pharmaceuticals?
Telix Pharmaceuticals (TLX) is larger, with a market capitalization of $3.75B compared with $3.51B for Xenon Pharmaceuticals (XENE).
Which stock has performed better over the past year, TLX or XENE?
TLX returned +11.76% over the past 12 months, compared with -7.02% for XENE (price return, excluding dividends). Past performance does not predict future results.
Are Telix Pharmaceuticals and Xenon Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.